YP1A Stock Overview
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Immutep Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$2.24 |
52 Week High | AU$2.90 |
52 Week Low | AU$1.35 |
Beta | 1.81 |
1 Month Change | 10.89% |
3 Month Change | 9.80% |
1 Year Change | 50.34% |
3 Year Change | -7.44% |
5 Year Change | 15.46% |
Change since IPO | 48.44% |
Recent News & Updates
Recent updates
Shareholder Returns
YP1A | DE Biotechs | DE Market | |
---|---|---|---|
7D | 3.7% | 2.1% | 1.9% |
1Y | 50.3% | 37.0% | 7.3% |
Return vs Industry: YP1A exceeded the German Biotechs industry which returned 35.8% over the past year.
Return vs Market: YP1A exceeded the German Market which returned 6.4% over the past year.
Price Volatility
YP1A volatility | |
---|---|
YP1A Average Weekly Movement | 9.9% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: YP1A has not had significant price volatility in the past 3 months.
Volatility Over Time: YP1A's weekly volatility has decreased from 17% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | n/a | Marc Voigt | https://www.immutep.com |
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease.
Immutep Limited Fundamentals Summary
YP1A fundamental statistics | |
---|---|
Market cap | €275.99m |
Earnings (TTM) | -€24.42m |
Revenue (TTM) | €2.37m |
116.4x
P/S Ratio-11.3x
P/E RatioIs YP1A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
YP1A income statement (TTM) | |
---|---|
Revenue | AU$3.93m |
Cost of Revenue | AU$37.72m |
Gross Profit | -AU$33.79m |
Other Expenses | AU$6.71m |
Earnings | -AU$40.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.034 |
Gross Margin | -859.57% |
Net Profit Margin | -1,030.32% |
Debt/Equity Ratio | 0.8% |
How did YP1A perform over the long term?
See historical performance and comparison